M Nicolò1, D Ghiglione, G Calabria. 1. Department of Neuroscience, Ophthalmology and Genetics, University Eye Clinic and Ist. Biosanitas, Genova, Italy. massimonicolo@occhioallaretina.it
Abstract
PURPOSE: To report one case of retinal pigment epithelium tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. METHODS: A 59-year-old patient presented with occult choroidal neovascularization associated with a serous pigment epithelial detachment secondary to age-related macular degeneration. The patient was treated with an intravitreal injection of bevacizumab. RESULTS: The patient developed a retinal pigment epithelium tear 60 days following the intravitreal injection. CONCLUSIONS: This report describes the development of retinal pigment epithelium tear after intravitreal bevacizumab injection. Future studies should be performed to evaluate which subtypes of lesions are most susceptible to this potential devastating visual complication.
PURPOSE: To report one case of retinal pigment epithelium tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. METHODS: A 59-year-old patient presented with occult choroidal neovascularization associated with a serous pigment epithelial detachment secondary to age-related macular degeneration. The patient was treated with an intravitreal injection of bevacizumab. RESULTS: The patient developed a retinal pigment epithelium tear 60 days following the intravitreal injection. CONCLUSIONS: This report describes the development of retinal pigment epithelium tear after intravitreal bevacizumab injection. Future studies should be performed to evaluate which subtypes of lesions are most susceptible to this potential devastating visual complication.